1. In Vivo
  2. >>Deal-Making

Going More Than Skin Deep Into Merz’s Ulthera Acquisition

New Enterprise Associates registered one of its biggest returns ever when Merz agreed to pay up to $600 million for aesthetics company Ulthera. CEO Matthew Likens and lead investor Justin Klein, MD, discuss specifics about the blockbuster deal.

As the hurdles for regulatory approval and reimbursement have risen higher, medtech investors often have pursued investments in aesthetics companies. In contrast to more traditional medtech, aesthetics companies typically aren’t required to conduct stringent clinical testing as they can bring a product to market with a 510(k) notification from the Food and Drug Administration. Also, patients eager to maintain the appearance of youth and good health are willing to pay for procedures out of their own pockets. This enables aesthetics companies to avoid the byzantine reimbursement process.

However, for venture investors, the lowest hanging fruit isn’t always the most nutritious. Venture capital investment exits from aesthetics companies...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deal-Making

Dealmaking Quarterly Statistics, Q2 2025

 
• By Maureen Riordan and Deanna Kamienski

During Q2, biopharma merger and acquisition deal value reached $24.6bn and drew in $60.7bn in potential deal value from alliances. Device company M&A values reached $223m, while in vitro diagnostics and research tools players’ M&A activity totaled $802m.

Financing Quarterly Statistics, Q2 2025

 
• By Deanna Kamienski and Maureen Riordan

During Q2, biopharmas brought in an aggregate $17.5bn in financing and device company fundraising totaled $2.7bn; while in vitro diagnostic firms and research tools players raised $1.7bn

Geopolitical Volatility Not Dimming A Healthy Mid-Term Outlook For Life Sciences Deals

 
• By Ashley Yeo

New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By Barnaby Pickering

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.

More from In Vivo

Dealmaking Quarterly Statistics, Q2 2025

 
• By Maureen Riordan and Deanna Kamienski

During Q2, biopharma merger and acquisition deal value reached $24.6bn and drew in $60.7bn in potential deal value from alliances. Device company M&A values reached $223m, while in vitro diagnostics and research tools players’ M&A activity totaled $802m.

PBMs Tighten The Reins: Value Becomes The New Access Gatekeeper

 
• By Andrew Cox

Facing rising costs and tighter regulations, PBMs and insurers are accelerating the shift to value-based drug coverage, demanding stronger proof of therapeutic and economic benefit from pharma.

Akelos’ Peripheral HCN1 Blocker Looks To End Opioid Dependence In Neuropathic Pain

 
• By Jo Shorthouse

Akelos is developing a first-in-class, non-addictive HCN1 inhibitor for peripheral neuropathic pain, based on anesthesiology research from Weill Cornell. The compound is designed to avoid the brain and heart, and has shown strong preclinical efficacy and safety with NIH backed development underway.